| Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor H Harrison, G Farnie, SJ Howell, RE Rock, S Stylianou, KR Brennan, ... Cancer research 70 (2), 709-718, 2010 | 658 | 2010 |
| Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer SA Eccles, EO Aboagye, S Ali, AS Anderson, J Armes, F Berditchevski, ... Breast Cancer Research 15, 1-37, 2013 | 514 | 2013 |
| Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells JK Singh, BM Simões, SJ Howell, G Farnie, RB Clarke Breast Cancer Research 15, 1-9, 2013 | 283 | 2013 |
| Origins of breast cancer subtypes and therapeutic implications AH Sims, A Howell, SJ Howell, RB Clarke Nature Clinical Practice Oncology 4 (9), 516-525, 2007 | 276 | 2007 |
| Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and-independent mechanisms JK Singh, G Farnie, NJ Bundred, BM Simões, A Shergill, G Landberg, ... Clinical cancer research 19 (3), 643-656, 2013 | 244 | 2013 |
| Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer RE Board, AM Wardley, JM Dixon, AC Armstrong, S Howell, L Renshaw, ... Breast cancer research and treatment 120, 461-467, 2010 | 236 | 2010 |
| The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer SJ Howell, SRD Johnston, A Howell Best practice & research Clinical endocrinology & metabolism 18 (1), 47-66, 2004 | 235 | 2004 |
| Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a … RH Jones, A Casbard, M Carucci, C Cox, R Butler, F Alchami, TA Madden, ... The Lancet Oncology 21 (3), 345-357, 2020 | 203 | 2020 |
| Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity BM Simoes, CS O’Brien, R Eyre, A Silva, L Yu, A Sarmiento-Castro, ... Cell reports 12 (12), 1968-1977, 2015 | 195 | 2015 |
| Capivasertib in hormone receptor–positive advanced breast cancer NC Turner, M Oliveira, SJ Howell, F Dalenc, J Cortes, HL Gomez Moreno, ... New England Journal of Medicine 388 (22), 2058-2070, 2023 | 171 | 2023 |
| Impaired tamoxifen metabolism reduces survival in familial breast cancer patients WG Newman, KD Hadfield, A Latif, SA Roberts, A Shenton, C McHague, ... Clinical Cancer Research 14 (18), 5913-5918, 2008 | 144 | 2008 |
| Breast cancer: current and future endocrine therapies C Palmieri, DK Patten, A Januszewski, G Zucchini, SJ Howell Molecular and cellular endocrinology 382 (1), 695-723, 2014 | 140 | 2014 |
| Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin’s lymphoma AJ Davies, AZS Rohatiner, S Howell, KE Britton, SE Owens, IN Micallef, ... Journal of clinical oncology 22 (8), 1469-1479, 2004 | 135 | 2004 |
| The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre SJ Howell, M Grey, J Chang, GR Morgenstern, RA Cowan, DP Deakin, ... British journal of haematology 119 (2), 408-411, 2002 | 135 | 2002 |
| HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials S Dent, B Oyan, A Honig, M Mano, S Howell Cancer treatment reviews 39 (6), 622-631, 2013 | 129 | 2013 |
| Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling R Eyre, DG Alférez, A Santiago-Gómez, K Spence, JC McConnell, C Hart, ... Nature communications 10 (1), 5016, 2019 | 128 | 2019 |
| Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy R Lamb, M Fiorillo, A Chadwick, B Ozsvari, KJ Reeves, DL Smith, ... Oncotarget 6 (16), 14005, 2015 | 115 | 2015 |
| Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling H Harrison, BM Simões, L Rogerson, SJ Howell, G Landberg, RB Clarke Breast Cancer Research 15, 1-12, 2013 | 110 | 2013 |
| Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer … SJ Howell, A Casbard, M Carucci, K Ingarfield, R Butler, S Morgan, ... The Lancet Oncology 23 (7), 851-864, 2022 | 99 | 2022 |
| Facilitating reproductive choices: the impact of health services on the experiences of young women with breast cancer RJ Lee, A Wakefield, S Foy, SJ Howell, AM Wardley, AC Armstrong Psycho‐oncology 20 (10), 1044-1052, 2011 | 95 | 2011 |
